Sernova Biotherapeutics Income Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	2020 - 2016
Selling, General & Admin	7.52	8.97	8.46	7.86	2.3	Upgrade
Research & Development	7.5	22.69	32.04	16.9	4.64	Upgrade
Operating Expenses	15.02	31.66	40.5	24.75	6.94	Upgrade
Operating Income	-15.02	-31.66	-40.5	-24.75	-6.94	Upgrade
Interest Expense	-0.75	-0.59	-0.03	-0.05	-0.01	Upgrade
Interest & Investment Income	0.03	0.39	1.5	0.58	0.07	Upgrade
Currency Exchange Gain (Loss)	-0.04	-0.34	0.04	-0.13	-0.04	Upgrade
Other Non Operating Income (Expenses)	-	-	-	-0.07	-0.05	Upgrade
EBT Excluding Unusual Items	-15.79	-32.2	-39	-24.42	-6.97	Upgrade
Gain (Loss) on Sale of Assets	0.06	0.02	-	-	-	Upgrade
Pretax Income	-15.73	-32.19	-39	-24.42	-6.97	Upgrade
Income Tax Expense	0.01	0.01	-	-	-	Upgrade
Net Income	-15.74	-32.19	-39	-24.42	-6.97	Upgrade
Net Income to Common	-15.74	-32.19	-39	-24.42	-6.97	Upgrade
Shares Outstanding (Basic)	328	307	303	274	246	Upgrade
Shares Outstanding (Diluted)	328	307	303	274	246	Upgrade
Shares Change (YoY)	6.95%	1.19%	10.87%	11.43%	24.45%	Upgrade
EPS (Basic)	-0.05	-0.10	-0.13	-0.09	-0.03	Upgrade
EPS (Diluted)	-0.05	-0.10	-0.13	-0.09	-0.03	Upgrade
Free Cash Flow	-10.91	-18.9	-30.44	-14.75	-6.86	Upgrade
Free Cash Flow Per Share	-0.03	-0.06	-0.10	-0.05	-0.03	Upgrade
EBITDA	-14.77	-31.25	-40.19	-24.45	-6.69	Upgrade
D&A For EBITDA	0.26	0.41	0.31	0.3	0.24	Upgrade
EBIT	-15.02	-31.66	-40.5	-24.75	-6.94	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.